Drug super spender tsunami: An integrated medical and pharmacy benefits assessment

BACKGROUND: As new rare-disease drug therapy, gene therapies, and high-priced cancer drugs receive US Food and Drug Administration approval, there is an increasing potential for drug super spender individuals with more than $250,000 annual drug cost. OBJECTIVE: To categorize all members in a large,...

Descripción completa

Detalles Bibliográficos
Autores principales: Starner, Catherine I, Bowen, Kevin, Gleason, Patrick P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373036/
https://www.ncbi.nlm.nih.gov/pubmed/36282927
http://dx.doi.org/10.18553/jmcp.2022.28.11.1200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373036/
https://www.ncbi.nlm.nih.gov/pubmed/36282927
http://dx.doi.org/10.18553/jmcp.2022.28.11.1200

Ejemplares similares